New Castle, DE – October 3, 2018 – Companion Animal Health® is pleased to announce they have secured an exclusive commercialization partnership with Nanospectra Biosciences, Inc. of Houston, TX. Nanospectra Biosciences is a medical device company who is focused on pioneering a patient-centric use of nanomedicine for selective thermal ablation of solid tumors.
In 2017, Companion Animal Health initiated clinical trials in the treatment of canine mast cell tumors using a combined laser and nanoshell therapy procedure that has the ability to destroy solid tumors without damaging adjacent healthy tissue.
Brian Pryor, PhD CEO, LiteCure, LLC, says, “Initial results are very encouraging and we anticipate publishing trial outcomes in the near future. We believe this approach will deliver superior efficacy compared to commonly used cancer treatments and will extend pets’ quality of life and longevity without harmful side effects.”
Dr. Lisa Parshley will be presenting the initial findings from her pilot study at the upcoming Veterinary Cancer Society meeting on Saturday, October 20th at 11:30 AM. Click here for more information about the presentation.
About Companion Animal Health
Education – Evidence – Partnership
Companion Animal Health is US-based animal health company committed to improving the quality of life for animals through innovative healthcare solutions, designed to provide superior outcomes at every stage of care. Companion works closely with veterinary professionals to identify industry needs and develop products with a demonstrated and evidence-backed ability to fulfill those needs. Offering on-going educational opportunities and industry-leading customer care, Companion partners with its customers to deliver both the products and support required to provide the best care possible at every step in the animal healthcare journey.
For More Information Contact
Amanda Hoffmeyer
Director of Marketing
amandah@litecure.com
302-709-0408 x1569
101 Lukens Drive, Suite A
New Castle, DE 19720